KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.

Nikita Sushentsev, Anne Y Warren, Richard Colling, Clare Verrill, Ekaterina Pazukhina, Oleg Blyuss, Alexey Zaikin, Tyler M Seibert, Tristan Barrett, Jon Oxley, Ian G Mills, Richard J Bryant, J Athene Lane, Jenny L Donovan, David E Neal, Freddie C Hamdy

BJU Int 137(6) 984-991

PMID41896701
PMCIDPMC13168917
DOI10.1111/bju.70261
发表日期2026-03-28
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

OBJECTIVES: To retrospectively analyse the results of the Prostate Testing for Cancer and Treatment (ProtecT; ClinicalTrials.gov identifier: NCT02044172) trial to establish the association between cribriform-positive and -negative prostate cancer (PCa) and the 15-year risk of metastasis or death from PCa in patients who underwent radical prostatectomy (RP). PATIENTS AND METHODS: Between 1999 and 2009, the ProtecT phase 3 clinical trial enrolled 1643 men with clinically localised PCa who were randomised to receive active monitoring, RP, or radiotherapy. In this secondary analysis of the trial, a centralised histopathological review was conducted on available RP pathology slides to classify patients as cribriform-positive if they had invasive cribriform carcinoma and/or intraductal carcinoma. The primary outcome was a composite of progression to metastatic disease or death from PCa. Exposures included age, prostate-specific antigen density, RP Grade Group (GG), pathological T stage (pT), and cribriform status. Multivariable Cox proportional hazards regression models assessed 15-year risk. Cumulative incidence curves were compared using the Gray test. RESULTS: Of 480 men with RP specimens reviewed, 143 (30%) had cribriform-positive disease and 337 (70%) had cribriform-negative disease. All 21 metastatic or lethal events occurred exclusively in the cribriform-positive group (15-year cumulative incidence 14%). Within the cribriform-positive cohort, risk was concentrated in patients with pT3b stage and/or GG ≥3 (15-year cumulative incidence 27%). In multivariable analysis of cribriform-positive patients, pT3b stage (hazard ratio [HR] 8.19, 95% confidence interval [CI] 2.39-28.10; P < 0.001) and GG 3 disease (HR 5.12, 95% CI 1.59-16.40; P = 0.006) were independent predictors of adverse outcomes. Conversely, cribriform-positive patients with GG 2 and ≤pT3a had a 15-year event rate of only 3%. CONCLUSION: In the ProtecT trial, the 15-year risk of metastasis or death after RP was a binary outcome defined by cribriform status. The concentration of risk in men with cribriform-positive, high-grade and/or pT3b tumours identifies a target population for adjuvant therapy trials, while supporting management de-escalation for most RP patients.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 3

Primary outcome analysis in the treatment‐received cohort. (A, B) Data are from the treatment‐received cohort. Numbers at risk for Group 1 correspond to cribriform‐positive patients with GG 2 and ≤pT3a disease; similar numbers for Group 2 correspond to cribriform‐positive patients with GG ≥3 and/or pT3b disease. Two‐sided P values were calculated using Gray's test. (C) Multivariable Cox proportional‐hazard model plot for treatment‐received cohort, with diamonds indicating HRs and horizontal lines indicating 95% CIs, with corresponding two‐sided P values provided as appropriate.

A

Cumulative incidence of biochemical recurrence

Fig. 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
B

Cumulative incidence of biochemical recurrence

Fig. 3 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Study flowchart.
非 KM Figure
Fig. 2Primary outcome cumulative incidence analysis in the per‐protocol cohort. (A) Data are from a 15‐year cumulative analysis of the full per‐protocol cohort. (B) Data are from a 15‐year cumulative incidence analysis of two subgroups of cribriform‐positive patients from the per‐protocol cohort. Numbers at risk for Group 1 correspond to cribriform‐positive patients with GG 2 and ≤pT3a disease; similar numbers for Group 2 correspond to cribriform‐positive patients with GG ≥3 and/or pT3b disease. Two‐sided P values were calculated using Gray's test.
非 KM Figure